Spiber Inc. Raises Jpy 34.4 Billion In Funding To Strengthen Production And Sales Network
09/08/21, 6:29 PM
Location
yamagata
Spiber (Director and Representative Executive Officer: Kazuhide Sekiyama), a biomanufacturing startup, announced that it has approved a capital increase of JPY 24.4 billion yen through an equity investment round which includes leading global investors such as Carlyle (Japan representative: Kazuhiro Yamada), as well as from existing shareholders such as Cool Japan Fund Inc. (President and CEO: Kenichi Kawasaki).
Company Info
Location
yamagata, yamagata, jpn
Additional Info
Established in September 2007, Spiber Inc. is a Japanese biotechnology startup utilizing cutting-edge synthetic biology, polymer, and material science for the development of its novel Brewed Protein™ materials. Produced through microbial fermentation and utilizing agricultural feedstocks as primary raw materials, Brewed Protein™ polymers are well-positioned to make significant contributions to animal- and plastic-free initiatives in a range of fields such as the apparel and automotive industries. Leveraging its R&D expertise, Spiber pursues its mission of positively contributing to sustainable human well-being. Operation of Spiber’s first mass production plant in Rayong Province, Thailand, is slated to commence within 2021. The company is also constructing a second mass production facility with partner ADM in Iowa, USA, which is scheduled to begin operating in 2023 at the earliest. Further information is available at https://www.spiber.inc/en/
Post-money valuation after the completion of this round: approximately JPY 133 billion.
Offering price per share: JPY 4,500. Number of outstanding shares (excluding treasury stock) after this capital increase: 29,565,875 shares.